Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Neuroendocrine Tumors
Related studies linked through entity extraction aliases.
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)
- Status
- RECRUITING
- Phase
- NA
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients with an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment
- Status
- COMPLETED
- Phase
- NA
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- N/A
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
- Status
- RECRUITING
- Phase
- N/A
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lutathera and ASTX727 in Neuroendocrine Tumours
- Status
- RECRUITING
- Phase
- PHASE1
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
- Status
- UNKNOWN
- Phase
- PHASE2
Open-label Study of Surufatinib in Japanese Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Neuroendocrine Tumors - Patient Reported Outcomes
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
- Status
- RECRUITING
- Phase
- PHASE1
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
- Status
- COMPLETED
- Phase
- NA